Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine Plus R-CHOP in Untreated DLBCL
NCT04974996Phase 1Withdrawn
- Sponsor
- ADC Therapeutics
- Start
- Feb 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by ADC Therapeutics. Primary endpoints: Number of Participants Who Experience Dose Limiting Toxicities, Number of Participants Who Experience a Treatment-emergent Adverse Event and 8 more. Planned start Feb 2022; status: withdrawn.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04974996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974996.